Creo Medical Group plc
("Creo" or the "Company")
Growth & Innovation Forum 2020
Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces it will be exhibiting at the Growth & Innovation Forum 2020 on Tuesday 11 February at the Business Design Centre, London N1.
Members of the CREO team will be at stand 2 throughout the day and Prof. Chris Hancock, CTO, will be presenting at 10.05am in the Babbage room.
This is a one-day investor event exhibiting companies focused on growth and technology, attracting both institutional and retail investors. For further information, please visit the event website at:
https://www.sharesmagazine.co.uk/events/event/growth-innovation-forum-2020-1
The presentation will be available on the Company website shortly after the event here: https://investors.creomedical.com/investors/reports-and-presentations/2019
If you are interested in attending the presentation and would like information on how to register, please contact Walbrook PR at [email protected]
No new material information will be disclosed at the event.
For further information, please contact:
Creo Medical Group plc |
|
Richard Rees (CFO) |
+44 (0)129 160 6005 |
|
|
Cenkos Securities |
+44 (0)20 7397 8900 |
Stephen Keys/Mark Connelly (NOMAD) |
|
Michael Johnson / Russell Kerr (Sales) |
|
|
|
Walbrook PR Ltd |
+44 (0)20 7933 8780 or [email protected] |
Paul McManus |
+44 (0)7980 541 893 |
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, investors.creomedical.com
